Michael T. Lotze
Impact in
- Immunology top 0.01%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Clinical Biochemistry top 0.01%
- Advanced Glycation End Products research
Papers in
- Immunology 282
- Immunotherapy and Immune Responses 157
- Immune Cell Function and Interaction 102
- T-cell and B-cell Immunology 57
- Immune Response and Inflammation 45
- Oncology 177
- Cancer Immunotherapy and Biomarkers 69
- CAR-T cell therapy research 68
- Co-authors
- Daolin Tang (74 shared papers)Herbert J. Zeh (98 shared papers)Rui Kang (46 shared papers)Steven A. Rosenberg (46 shared papers)Kevin J. Tracey (8 shared papers)Herbert J. Zeh (14 shared papers)Claudia A. Seipp (10 shared papers)Timothy R. Billiar (27 shared papers)
- Journals
- Journal of Immunotherapy (40 papers)The Journal of Immunology (34 papers)Journal of Clinical Oncology (24 papers)Cancer Research (14 papers)Journal of Leukocyte Biology (11 papers)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Michael T. Lotze
518 papers receiving 58.7k citations
Michael T. Lotze's Hit Papers
Peers
Comparison fields: 5 of 183
- Immunology 25.1k
- Clinical Biochemistry 6.0k
- Oncology 16.2k
- Cancer Research 6.0k
- Molecular Biology 19.3k
Countries citing papers authored by Michael T. Lotze
This map shows the geographic impact of Michael T. Lotze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael T. Lotze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael T. Lotze more than expected).
Fields of papers citing papers by Michael T. Lotze
This network shows the impact of papers produced by Michael T. Lotze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael T. Lotze. The network helps show where Michael T. Lotze may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael T. Lotze, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 531 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone Hit paper breakdown → | 1987 | 2351 |
| 2 | Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer Hit paper breakdown → | 1985 | 2148 |
| 3 | High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal Hit paper breakdown → | 2005 | 2117 |
| 4 | The Beclin 1 network regulates autophagy and apoptosis Hit paper breakdown → | 2011 | 2063 |
| 5 | Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma Hit paper breakdown → | 1988 | 1906 |
| 6 | Autophagy promotes ferroptosis by degradation of ferritin Hit paper breakdown → | 2016 | 1855 |
| 7 | High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 Hit paper breakdown → | 1999 | 1630 |
| 8 | Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma Hit paper breakdown → | 2008 | 1334 |
| 9 | Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction Hit paper breakdown → | 1990 | 1011 |
| 10 | 2012 | 974 | |
| 11 | The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion Hit paper breakdown → | 2005 | 972 |
| 12 | Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients Hit paper breakdown → | 1989 | 848 |
| 13 | Endogenous HMGB1 regulates autophagy Hit paper breakdown → | 2010 | 809 |
| 14 | HMGB1 in health and disease Hit paper breakdown → | 2014 | 809 |
| 15 | The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity Hit paper breakdown → | 2017 | 777 |
| 16 | Principles and Current Strategies for Targeting Autophagy for Cancer Treatment Hit paper breakdown → | 2011 | 756 |
| 17 | Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. Hit paper breakdown → | 1996 | 736 |
| 18 | AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc– Activity Hit paper breakdown → | 2018 | 615 |
| 19 | Inflammation and necrosis promote tumour growth Hit paper breakdown → | 2004 | 571 |
| 20 | The grateful dead: damage‐associated molecular pattern molecules and reduction/oxidation regulate immunity Hit paper breakdown → | 2007 | 532 |
About Michael T. Lotze
Michael T. Lotze is a scholar working on Immunology, Oncology, Molecular Biology, Clinical Biochemistry and Genetics, having authored 531 papers that have together received 60.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (157 papers), Immune Cell Function and Interaction (102 papers), Advanced Glycation End Products research (76 papers), Cancer Immunotherapy and Biomarkers (69 papers), CAR-T cell therapy research (68 papers), T-cell and B-cell Immunology (57 papers), Virus-based gene therapy research (46 papers) and Immune Response and Inflammation (45 papers). The work is most often cited by research in Immunology (25.1k citations), Clinical Biochemistry (6.0k citations), Oncology (16.2k citations), Cancer Research (6.0k citations) and Molecular Biology (19.3k citations). Michael T. Lotze has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Daolin Tang, Herbert J. Zeh, Rui Kang, Steven A. Rosenberg, Kevin J. Tracey, Herbert J. Zeh, Claudia A. Seipp, Timothy R. Billiar, Walter J. Storkus and R Kang. Their work appears in journals such as Journal of Immunotherapy, The Journal of Immunology, Journal of Clinical Oncology, Cancer Research and Journal of Leukocyte Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.